Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy

Kidney International, Supplement

Volumn 55, Issue 69, 1999, Pages

  Eschbach, Joseph W ^a   Adamson, John W ^b  

^a Minor and James Medical   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN; FREE RADICAL;

ANEMIA; BACTERIAL INFECTION; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HEMODIALYSIS; HUMAN; IRON OVERLOAD; KIDNEY FAILURE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; CHRONIC KIDNEY FAILURE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANEMIA; BACTERIAL INFECTIONS; ERYTHROPOIETIN, RECOMBINANT; FREE RADICALS; HUMANS; IRON; IRON OVERLOAD; KIDNEY FAILURE, CHRONIC;

EID: 0032915658     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.055suppl.69035.x     Document Type: Review

References (70)

1. COUNCIL ON FOOD, NUTRITION COMMITTEE ON IRON DEFICIENCY: Iron deficiency in the United States. JAMA 203:119-124, 1968
2. HASKINS D, STEVENS AR JR, FINCH S, FINCH CA: Iron metabolism: Iron stores in man as measured by phlebotomy. J Clin Invest 31:543-547, 1952
3. FINCH SC, FINCH CA: Idiopathic hemochromatosis, an iron storage disease. Medicine 34:381-430, 1955
4. SCHAFER AI, CHERON RG, DULHY R, COOPER B, GLEASON RE, SOELDER JS, BUNN HF: Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 304:319-325, 1981
5. ALI M, FAYEMI AO, RIGOLOSI R, FRASCINO J, MARSDEN JT, MALCOM D: Hemosiderosis in bemodialysis patients: An autopsy study of 50 cases. JAMA 244:343-345, 1980
6. HAKIM RM, SHVELMAN JC, SCHULMAN G, FOSBURU M, WOLFE L, IMBER MJ, LAZARUS JM: Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis 10:293-299, 1987
7. SHVELMAN J, SCHULMAN G, FOSBURG M, LAZARUS JM, HAKIM RM: Kinetics and efficacy of deteroxamine in iron-overloaded hemodialysis patients. Kidney Int 36:1125-1132, 1989
8. BOTTOMLEY SS: Secondary iron overload disorders. Semin Hematol 35:77-86, 1998
9. ESCHBACH JW, FUNK D, ADAMSON J, KUHN I, SCRIBNER BH, FINCH CA: Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med 276:653-658, 1967
10. PONKA P, BEAUMONT C, RICHARDSON DR: Function and regulation of transferrin and ferritin. Semin Hematol 35:35-54, 1998
11. WEISS G, HOUSTON T, KASTNER S, JOHRER K, GRUNEWALD K, BROCK JH: Regulation of cellular iron metabolism by erythropoietin: Activation of iron-regulatory protein and upregulation of transferrin receptor expression in erythroid cells. Blood 89:680-687, 1997
12. ALJAMA P, WARD MK, PIERIDES AM, EASTHAM EJ, ELLIS HA, FEEST TG, CONCEICAO S, KERR DNS: Serum ferritin concentration: A reliable guide to iron overload in uremic and hemodialyzed patients. Clin Nephrol 10:101-104, 1978
13. MCCARTHY JT, JOHNSON WJ, NIXON DE, JENSON BM, MOYER TP: Transfusional iron overload in patients undergoing dialysis: Treatment with erythropoietin and phlebotomy. J Lab Clin Med 114: 193-199, 1989
14. ONOYAMA K, NAKAMURA S, YAMAMOTO M, KAWADOKO T, NANISHI F, KOMODA T, MURAI K, FUJISHIMA M: Correction of serious iron overload in a chronic hemodialysis patient by recombinant human erythropoietin and removal of red blood cells: Confirmation by follow-up liver biopsy. Nephron 56:325-328, 1990
15. CHAN PCK, LUI P, CRONIN C, HEATHCOTE J, ULDALL R: The use of nuclear magnetic resonance imaging in monitoring total body iron in hemodialysis patients with hemosiderosis treated with erythropoietin and phlebotomy. Am J Kidney Dis 19:484-489, 1992
16. STANBAUGH GH, GILLIT DM, HOLMES AW: Dialysis hemosiderosis mimicking non-A, non-B hepatitis. Trans Am Soc Artif Intern Organs 30:217-221, 1984
17. GOKAL R, MILLARD PR, WEATHERALL DJ, CALLENDER STE, LEDINGHAM JGG, OLIVER DO: Iron metabolism in haemodialysis patients: A study of the management of iron therapy and overload. Q J Med 48:369-391, 1979
18. GOKAL R, WEATHERALL DJ, BUNCH C: Iron induced increase in red cell size in haemodialysis patients. Q J Med 48:393-401, 1979
19. LAZARUS JM, HAKIM RM, NEWELL J: Recombinant human erythropoietin and phlebotomy in the treatment of iron overload in chronic hemodialysis patients. Am J Kidney Dis 16:101-108, 1990
20. VERROUST PJ, CURTIS JR, WING AJ, EASTWOOD JB, STOREY J, EDWARDS MS, DE WARDENER HE: Intermittent haemodialysis without routine blood transfusions. Proc Eur Dial Transplant Assoc 4:12-16, 1967
21. LONGNECKER RE, GOFFINET JA, HENDLER ED: Blood loss during maintenance hemodialysis. Trans Am Soc Artif Intern Organs 20:135-141, 1974
22. LINDSAY RM, BURTON JA, EDWARD N, DARGIE HJ, PRENTICE CRM, KENNEDY AC: Dialyzer blood loss. Clin Nephrol 1:29-34, 1973
23. KOCH KM, BECHSTEIN PB, FASSBINDER W, KALTWASSER P, SCHOEPPE W, WERNER E: Occult blood loss and iron balance in chronic renal failure. Proc Eur Dial Transplant Assoc 12:362-369, 1975
24. MCGONIGLE RJS, KEOGH AM, WESTON MJ, PARSONS V: Iron status in chronic hemodialysis patients: Treatment of transfusional iron overload with desferrioxamine. Dial Transplant 13:214-219, 1984
25. KRUMLOVSKY FA: Desferrioxamine in the management of dialysis hemosiderosis. Int J Artif Organs 5:223-225, 1982
26. FALK RJ, MATTERN WD, LAMANNA RW, GITELMAN HJ, PARKER NC, CROSS RE, RASTALL JR: Iron removal during continuous ambulatory peritoneal dialysis using deferoxamine. Kidney Int 24:110-112, 1983
27. BAKER LRI, BARNETT MD, BROZOVIC B, CATTELL WR, ACKRJLL P, MCALISTER J, NIMMON C: Hemosiderosis in a patient on regular hemodialysis: Treatment by desferrioxamine. Clin Nephrol 6:326-328, 1976
28. TISHER CC, BARNETT BMS, FINCH CA, SCRIBNER BH: Treatment of iron overload in patients with renal failure. Clin Sci 33:539-548, 1967
29. ALI M, FAYEMI AO, FRASCINO J, RIGOLOSI R, BRAUN EV, SINGER R: Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1 652-655, 1982
30. PITTS TO, BARBOUR GL: Hemosiderosis secondary to chronic parenteral iron therapy in maintenance hemodialysis patients. Nephron 22:316-321, 1978
31. NOMURA S, OSAWA G, KARAI M: Treatment of a patient with end-stage renal disease, severe iron overload and ascites by weekly phlebotomy combined with recombinant human erythropoietin. Nephron 55:210-213, 1990
32. VAN DE VYVER FL, VANHEULE AO, VERBUEKEN AH, D'HAESE P, VISSER WJ, BEKAERT AB, VAN GRIEKEN RE, BUYSSENS N, DE KEERSMAECKER W, VAN DEN BOGAERT W, DE BROE ME: Patterns of iron storage in patients with severe renal failure. Contrib Nephrol 38:153-166, 1984
33. SAVEN A, BEUTLER E: Iron overload after prolonged intramuscular iron therapy. (letter to the editor) N Engl J Med 321:331-332, 1989
34. BOUCHER E, BOURIENNE A, ADAMS P, TURLIN B, BRISSOT P, DEUGNIER Y: Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut 41:115-120, 1997
35. BROWN EB JR, DUBACH R, SMITH SE, REYNAFARJE C, MOORE CV: Studies in iron transportation and metabolism. X. Long-term iron overload in dogs. J Lab Clin Med 50:862-893, 1957
36. FINCH CA, HEGSTED M, KINNEY TD, THOMAS ED, RATH CE, HASKINS D, FINCH S: Iron metabolism: The pathophysiology of iron storage. Blood 5:983-1008, 1950
37. CROWLEY JP, NEALEY TA, METZGER J, PONO L, CHAZAN JA: Transfusion and long-term hemodiaiysis. Arch Intern Med 147:1925-1928, 1987
38. ESCHBACH JW, EGRIE JC, DOWNING MR, BROWNE JK, ADAMSON JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
39. ESCHBACH JW, ABDULHADI MH, BROWNE JK, DELANO BG, DOWNING MR, EGRIE JC, EVANS RW, FRIEDMAN EA, GRABER SE, HALEY NR, KORBET S, KRANTZ SB, LUNDIN AP, NISSENSON AR, ODGEN DA, PAGANINI EP, RADER B, RUTSKY EA, STIVELMAN J, STONE WJ, TESCHAN P, VAN STONE JC, VAN WYCK DB, ZUCKERMAN K, ADAMSON J: Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial. Ann Intern Med 111:992-1000, 1989
40. SUNDER-PLASSMANN G, HÖRL WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076, 1995
41. ESCHBACH JW, HALEY NR, EGRIE JC, ADAMSON JW: A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney Int 42:407-416, 1992
42. ESCHBACH JW, HALEY NR, AQUILING T, BROWNE JK, DOWNING MR, EGRIE JC, ADAMSON JW: Three years of erythropoietin (rHuEPO) therapy. (abstract) Kidney Int 37:237, 1990
43. UNITED STATES RENAL DATA SYSTEM. The USKDS Dialysis Morbidity and Mortality Study (wave 1), in U.S. Renal Data System 1996 Annual Data Report 4, Bethesda, National Institutes of Health, National Institute Diabetes and Digestive and Kidney Diseases. 1996, pp 45-67
44. Deleted in proof.
45. BREGMAN H, GELFAND MC, MANZ HJ, WINCHESTER JF, KNEPSHIELD JH, SCHREINER GE: Iron-overload-associated myopathy in patients on maintenance haemodialysis: A histocompatibility-linked disorder. Lancet 2:882-885, 1980
46. EDWARDS CO, GRIFFEN LM, KAPLAN J, KUSHNER JP: Twenty-four hour variation of transferrin saturation in treated and untreated haemochromatosis homozygotes. J Intern Med 226:373-379, 1989
47. TACCONE-GALLUCCI M, DI NUCCI GD, MELONI C, VALERIA M, ADORNO D, ELLI M, MARIANI G, MANDELLI F, CASCLANI CU: Transfused and pharmacological iron: Relationship of overload to HLA antigens. Proc Eur Dial Transplant Assoc 20:150-155, 1983
48. MAHER ER, CURTIS JR: Serum ferritin in haemodialysis patients: Is there a relationship to 'haemochromatosisis alleles' HLA A3, B7 B14? Nephron 43:43-44, 1986
49. SALONEN JT, NYYSSONEN K, KORPELA H, TUOMILEHTO J, SEPPANEN R, SALONEN R: High stores iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 86:803-811, 1992
50. SEMPOS CT, LOOKER AC, GILLUM RF, MAKUC DM: Body iron stores and the risk of coronary heart disease. N Engl J Med 330:1119-1124, 1994
51. STEVENS SG, JONES DY, MICOZZI MS, TAYLOR PR: Body iron stores and the risk of cancer. N Engl J Med 319:1047-1052, 1988
52. SEIFERT A, VON HERRATH D, SCHAEFER K: Iron overload. but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med 65:1015-1024, 1987
53. HOEN B, KESSLER M, HESTIN D, MAYEUX D: Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey. Nephrol Dial Transplant 10:377-381, 1995
54. BOELAERT JR, DANEELS RF, SCHURGERS ML, MATTHYS EG, GORDTS BZ, VAN LANDUYT HW: Iron overload in haemodialysis patients increases the risk of bacteraemia: A prospective study. Nephrol Dial Transplant 5:130-134, 1990
55. TIELELMANS CL, LENSLUD CM, WENS R, COLLART FE, DRATWA M: Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections: Beneficial effects of desferrioxamine. Nephrol Dial Transplant 4:883-887, 1989
56. FLAMENT J, GOLDMAN M, WATERLOT Y, DUPONT E, WYBRAN J, VANHENWEGHEM J-L: Impairment of phagocyte oxidative metabolism in hemodialvzed patients with iron overload. Clin Nephrol 25:227-230, 1986
57. CANTINIEAUX BF, BOELAERT J, HARIGA CF, FONDU P: Impaired neutrophil defense against Yersinia enterocolitica in patients with iron overload who are undergoing dialysis. J Clin Lab Med 111:524-528, 1988
58. VANHOLDER R, VAN BIESON W, RINGOIR S: Contributing factors to the inhibition of phagocytosis in hemodialvzed patients. Kidney Int 44:208-214, 1993
59. HOEN B, PAUL-DAUPHIN A, HESTIN D, KESSLER M: EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. Am J Nephrol 9:869-876, 1998
60. TIELEMANS C, ANDRE M, WILLEMS D: Plasma non-transferrin bound iron in haemodialysis patients. (abstract) Nephrol Dial Transplant 3:544-545, 1988
61. KESSLER M, HOEN B, MAYEUX D, HESTIN D, FONTENAILLE C: Bacteremia in patients on chronic hemodialysis. Nephron 64:95-100, 1993
62. PATRUTA SI, EDLINGER R, SUNDER-PLASSMANN G, HÖRL WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9:655-663, 1998
63. HERSHKO C, PETO TEA, WEATHERALL DJ: Iron and Infection. BMJ 296:660-664, 1988
64. UNITED STATES RENAL DATA SYSTEM 1997: Annual data report. VI. Causes of death. Am J Kidney Dis 30(Suppl 1):S107-S117, 1997
65. BOELAEBT JR, CANTINIEAUS BF, HARIGA CF, FONDU PG: Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overload dialysis patients. Nephrol Dial Transplant 5:504-507, 1990
66. VEYS N, VANHOLDER R, RINGOIR S: Correction of deficient phagocytosis during ervthropoietin (EPO) threatment in maintenance hemodialysis patients. Am J Kidney Dis 19:358-363, 1992
67. KLEIN HG: Immunologic aspects of blood transfusion. Semin Oncol 21:16-20, 1994
68. WARD CG: Iron and infection: New developments and their implications. J Trauma 41:356-364, 1996
69. HALLIWELL B, GUTTERIDGE JMC: Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol 186:1-85, 1990
70. BILIGA R, ZHANG Z, BALIGA M, UEDA N, SHAH S: In vitro and in vivo evidence suggesting a role for iron in cispiatin-induced nephrotoxicity. Kidney Int 53:394-401, 1998